and 0 ational



Documentation, Codebook, and Frequencies

Prostate Specific Antigen

Laboratory

Survey Years: 2005 to 2006

SAS Transport File: PSA_D.XPT

December 2007

NHANES 2005–2006 Data Documentation

Laboratory Assessment: Prostate specific antigen (PSA _D)

First Published: December 2007

Component Description	Prostate cancer is the most common non-skin malignancy among men with approximately 180,000 new cases diagnosed and 37,000 deaths in 1999. The total and free PSA tests have been recognized as tumor markers for the screening, diagnosis and management of prostate cancer.
	Total and free prostate specific antigens (PSA) were measured among men age 40 years and older. PSA exclusion questions (KIQ115, KIQ185, KIQ191, KIQ195, KIQ201, KIQ241, KIQ282, KIQ301, and KIQ311) were asked during the physician's examination. PSA immunoassays were performed on blood specimens using the Hybritech tests (Beckman Coulter, Fullerton, CA).
Eligible Sample	Male participants aged 40 years and older were tested for PSA. Those who reported having any of the following conditions were not eligible for PSA testing: Current infection or inflammation of the prostate gland (KIQ115) Rectal exam in the past week (KIQ185) Prostate biopsy in the past month (KIQ191) Cystoscopy in the past month (KIQ195) History of prostate cancer (KIQ201)
Description of Laboratory Methodology	Free prostate specific antigen The Access Hybritech free PSA assay is a two-site immunoenzymatic "sandwich" assay. A sample was added to a reaction vessel with mouse monoclonal anti-free PSA alkaline phosphatase conjugate, and paramagnetic particles coated with a second mouse monoclonal anti- free PSA antibody. The free PSA in the sample bound to the immobilized monoclonal anti-free PSA on the solid phase while, at the same time, the monoclonal anti-PSA conjugate reacted with a different antigenic site on the sample free PSA. Separation in a magnetic field and washing removes material not bound to the solid phase. A chemiluminescent substrate, Lumi-Phostm 530 was added to the reaction vessel and light generated by the reaction was measured with a luminometer. The light production was proportional to the concentration of free PSA in the sample. The amount of analyte in the

sample was determined by means of a stored, multi-point calibration curve.

Total prostate specific antigen

Total PSA values were obtained using the Hybritech PSA method on the Beckman Access. A second sample was added to a reaction vessel with mouse monoclonal anti-PSA alkaline phosphatase conjugate and paramagnetic particles coated with a second mouse monoclonal anti-PSA antibody. The PSA in the sample bound to the immobilized monoclonal anti-PSA on the solid phase while, at the same time, the monoclonal anti-PSA conjugate reacted with a different antigenic site on the sample PSA. The light production was proportional to the concentration of PSA in the sample.

Prostate specific antigen ratio

This ratio was calculated by dividing the free PSA by the total PSA: LBDP3 = round ((LBXP2/LBXP1)*100) (whole number)

There were no changes to the equipment, lab method, or lab site from the previous two years.

A detailed description of the laboratory method used can be found at NHANES web page.

Laboratory
QualityThe NHANES quality control and quality assurance protocols (QA/QC)
meet the 1988 Clinical Laboratory Improvement Act mandates.Control and
MonitoringDetailed quality control and quality assurance instructions are
discussed in the NHANES Laboratory/Medical Technologists
Procedures Manual (LPM). Read the LABDOC file for detailed QA/QC
protocols.

A detailed description of the quality assurance and quality control procedures can be found at NHANES web page.

DataBlood specimens are processed, stored and shipped to University ofProcessingWashington, Seattle, Washington. Detailed specimen collection andand Editingprocessing instructions are discussed in the NHANESLaboratory/Medical Technologists Procedures Manual (LPM). Read theLABDOC file for detailed data processing and editing protocols. The

analytical methods are described in the Analytic methodology section.

Because of the confidentiality of the data any male participant 86 years and older was recoded to "greater than 85". See the NHANES web page link to determine "below detectable limit fill values" for this data.

Analytic The analysis of NHANES 2005-2006 laboratory data must be conducted with the key survey design and basic demographic variables. The NHANES 2005-2006 Questionnaire Data Files contain demographic data, health indicators, and other related information collected during household interview and MEC examination. They also contain sample weights for these age groups. The phlebotomy file includes auxiliary information such as the conditions precluding venipuncture. The household questionnaire and phlebotomy files may be linked to the laboratory data file using the unique survey participant identifier SEQN.

Data on health conditions that would make a sample person ineligible for PSA testing are missing for some people with non-missing PSA lab data. This happened mainly because some sample persons did not attend the physician's examination component of the MEC examination where such data were collected. It is advisable to exclude these observations for PSA analyses.

References N/A

Locator Fields

Title: Prostate specific antigen (PSA)

Contact Number: 1-866-441-NCHS

Years of Content: 2005–2006

First Published: December 2007

Last Revised: N/A

Access Constraints: None

Use Constraints: None

Geographic Coverage: National

Subject: Prostate specific antigen (PSA)

Record Source: NHANES 2005–2006

Survey Methodology: NHANES 2005–2006 is a stratified multistage probability sample of the civilian

non-institutionalized population of the U.S.

Medium: NHANES Web site; SAS transport files

National Health and Nutrition Examination Survey Codebook for Data Production (2005-2006)

Laboratory Section: **Prostate Specific Antigen (PSA_D)**

December 2007



SEQN	Target			
	M(40 Yrs. to 150 Yrs.)			
Hard Edits	SAS Label			
	Respondent sequence number			
English Text: Respondent sequence number.				
English Instructions:	English Instructions:			

KIQ110			Т	arget			
MQ110			M(40 Yrs. to 150 Yrs.)				
Hard Edits			SA	S Label			
			Willing to have	blood tested for PSA	4		
English Text: Are you	ı willing to	have your blood te	sted for PSA?				
English Instructions:							
Code or Value	Ι	Description	Count	Cumulative	Skip to Item		
1		Yes	1315	1315			
2		No	27	1342			
7		Refused	0	1342			
9]	Don't know	0	1342			
		Missing	139	1481			

KIQ115			Target			
			M(40 Yrs. to 150 Yrs.)			
Hard Edits			SAS	Label		
			Infection or inflar	nmation of prostat	e	
English Text: {Do you	u/does SP}	have an infection of	r inflammation of t	ne prostate gland a	at the present time?	
English Instructions:						
Code or Value	Ι	Description	Count	Cumulative	Skip to Item	
1		Yes	16	16		
2		No	1404	1420		
7 Refused		0	1420			
9]	Don't know	7	1427		
•		Missing	54	1481		

KI0185	KIQ185		Target				
1112105			M(40 Yrs. to 150 Yrs.)				
Hard Edits			SAS	5 Label			
			Rectal exam	in the last 7 days			
English Text: {Have y	ou/Has SP	} had a rectal exam	in the last 7 days?				
English Instructions:							
Code or Value	I	Description	Count	Cumulative	Skip to Item		
1		Yes	13	13			
2		No	1414	1427			
7		Refused	0	1427			
9]	Don't know	0	1427			
		Missing	54	1481			

KIQ191			Target				
			M(40 Yrs. to 150 Yrs.)				
Hard Edits			SAS	Label			
			prostate biopsy or	surgery in last 4 w	ks		
English Text: {Have y	ou/Has SP	} had a prostate bio	psy or other prostat	e surgery in the la	st 4 weeks?		
English Instructions:							
Code or Value	Ι	Description	Count	Cumulative	Skip to Item		
1		Yes	4	4			
2		No	1423	1427			
7 Refused		0	1427				
9]	Don't know	0	1427			
		Missing	54	1481			

KIQ195	Target
MQ175	M(40 Yrs. to 150 Yrs.)
Hard Edits	SAS Label
	Cystoscopy in the last 4 weeks

English Text: {Have you/Has SP} had a cystoscopy in the last 4 weeks? (Cystoscopy is an internal examination of the prostate and bladder using a flexible tube-like instrument with a lens inserted through the penis.)

English Instructions:

Code or Value	Description	Count	Cumulative	Skip to Item
1	Yes	5	5	
2	No	1422	1427	
7	Refused	0	1427	
9	Don't know	0	1427	
•	Missing	54	1481	

KIQ201	Target			
	M(40 Yrs. to 150 Yrs.)			
Hard Edits	SAS Label			
	Diagnosed with prostate cancer			

English Text: {Have you/Has SP} ever been told by a doctor or health professional that {you/he} had prostate cancer?

English Instructions:

Code or Value	Description	Count	Cumulative	Skip to Item
1	Yes	59	59	
2	No	1367	1426	
7	Refused	0	1426	
9	Don't know	1	1427	
•	Missing	54	1481	

KID221	Target
	M(40 Yrs. to 150 Yrs.)
Hard Edits	SAS Label
	Age at diagnosis of prostate cancer

English Text: How old {were you/was SP} when {you were/he was} first told that {you/he} had prostate cancer?

English Instructions:

Code or Value	Description	Count	Cumulative	Skip to Item
•	•	0	0	
54	54	0	0	
58	58	0	0	
59	59	0	0	
60	60	0	0	
61	61	0	0	
62	62	0	0	
63	63	0	0	
64	64	0	0	
65	65	0	0	
66	66	0	0	
67	67	0	0	
68	68	0	0	
69	69	0	0	
70	70	0	0	
71	71	0	0	
72	72	0	0	
73	73	0	0	
75	75	0	0	
76	76	0	0	
77	77	0	0	
78	78	0	0	
79	79	0	0	
80	80	0	0	
81	81	0	0	
85 or greater	85 or greater	3	3	
< blank >	Missing	0	3	

KIQ241		Target					
ing211		M(40 Yrs. to 150 Yrs.)					
Hard Edits		SAS Label					
		Ever l	had pros	state surgery			
English Text: {Have yo	u/Has SP} ever had	surgery on {your/his}	prostat	æ?			
English Instructions:							
Code or Value	Description	n Cour	nt	Cumulative	Skip to Item		
1	Yes	24		24			
2	No	35		59			
7	Refused	0		59			
9	Don't know	0		59			
	Missing	1422	2	1481			

KIQ282		Target				
		M(40 Yrs. to 150 Yrs.)				
Hard Edits			SAS	Label		
			Surgery for p	rostate cancer?		
English Text: {Have y	you/Has SP	} had surgery for p	rostate cancer?			
English Instructions:						
Code or Value	Ι	Description	Count	Cumulative	Skip to Item	
1		Yes	19	19		
2		No	4	23		
7		Refused	0	23		
9	9 Don't know		1	24		
.]		Missing	1457	1481		

KIQ301		Target				
		M(40 Yrs. to 150 Yrs.)				
Hard Edits		SAS Label				
			Radiation treatme	ent for prostate canc	er	
English Text: {Have yo	u/Has SP]	ever had radiation	n treatments for pr	ostate cancer?		
English Instructions:						
Code or Value		escription	Count	Cumulative	Skip to Item	
1		Yes	33	33		
2		No	26	59		
7		Refused	0	59		
9	Γ	Oon't know	0	59		
•		Missing	1422	1481		

KIQ311		Target				
		M(40 Yrs. to 150 Yrs.)				
Hard Edits			SA	S Label		
			Taken medicine	es for prostate cance	er	
English Text: {Have y	ou/Has SP	} ever taken prescr	ibed medicines for	r prostate cancer?		
English Instructions:						
Code or Value	I	Description	Count	Cumulative	Skip to Item	
1		Yes	18	18		
2		No	40	58		
7		Refused	0	58		
9	9 De		1	59		
		Missing	1422	1481		

LBXP1		Target				
		M(40 Yrs. to 150 Yrs.)				
Hard Edit		SAS	5 Label			
		То	tal prostate spe	cific antigen (ng/ml	Ĺ)	
English Text: Total p	prostate spec	ific antigen (ng/mL)				
English Instructions:						
Code or Value	I	Description	Count	Cumulative	Skip to Item	
0.1 to 72.54	Range of Values		1317	1317		
0.07 At or below detection limit fill value		4	1321			
•	Missing		160	1481		

LBXP2		Target				
		M(40 Yrs. to 150 Yrs.)				
Hard Edits		SAS Label				
		Fr	ree prostate speci	fic antigen (ng/ml	L)	
English Text: Free pr	ostate speci	fic antigen (ng/mL)				
English Instructions	•					
Code or Value	Code or ValueDescriptionCountCumulativeSkip to It					
0.05 to 7.65	Range of Values		1308	1308		
0.04	0.04 At or below detection limit fill value		13	1321		
	. Missing		160	1481		

LBDP3		Target					
		M(40 Yrs. to 150 Yrs.)					
Hard Edits		SAS Label					
			Prostate specific	c antigen ratio (%)			
English Text: Prostate specific antigen ratio (%)							
English Instructions:	English Instructions:						
Code or Value	e or Value Description Count Cumulative Skip to Iten						
4 to 95 Range of V		nge of Values	1321	1321			
. Missing		160	1481				